News

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

More than three years after deeming COVID-19 a global health emergency, the World Health Organization ended the pandemic's special status in May.

This was certainly welcome news for numerous

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to

A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many

Over the past few years, several hot investing trends swept through Wall Street. First, it was the metaverse, and now it's artificial intelligence; there will likely be some new big thing in a year

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Pharma giant AbbVie (NYSE: ABBV) performed poorly in the first part of the year, especially after it reported its first-quarter results. This was its first quarterly update following the loss of

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

If you are looking for reliable dividend stocks that can provide steady income and growth in any market condition, you might want to consider these two blue chip companies that have proven their

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on.

Three Motley Fool contributors identified stocks that

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals